Literature DB >> 17201664

Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.

Viviana Buffa1, Donatella R M Negri, Pasqualina Leone, Martina Borghi, Roberta Bona, Zuleika Michelini, Daniela Compagnoni, Cecilia Sgadari, Barbara Ensoli, Andrea Cara.   

Abstract

Humoral and cellular immune responses have been shown to play a fundamental role in controlling simian and/or simian-human immunodeficiency virus (SIV-SHIV) replication in infected macaques. Therefore, the appropriate induction of both compartments of the immune system should be elicited after immunization. In this context, viral vectors have been proven effective in inducing both humoral and cellular immune responses during immunization protocols after direct injection in vivo. Among them, recombinant self-inactivating lentiviral vectors represent a useful strategy for vaccine development because they efficiently transduce and express foreign genes into a wide variety of mammalian cells. Here we report on the development and evaluation of a self-inactivating HIV-based lentiviral vector expressing a codon-optimized SIV Gag sequence (TY2-SIVGagDX), which when used to transduce dendritic cells mediated in vitro expansion of Gag-specific T cells derived from an SHIV-infected cynomolgus monkey, as measured by interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) and (51)Cr release standard assays. To evaluate the ability to elicit specific immune responses in vivo, TY2-SIVGagDX was also employed in a vaccination protocol after a single intramuscular injection in BALB/c mice. Results indicated that the vector was able to efficiently induce both cellular and humoral responses, as measured by IFN-gamma ELISPOT assay and antibody production. These data further confirm that lentiviral vectors encoding viral genes represent an advantageous delivery system for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201664     DOI: 10.1089/vim.2006.19.690

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  17 in total

Review 1.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice.

Authors:  Donatella R M Negri; Zuleika Michelini; Silvia Baroncelli; Massimo Spada; Silvia Vendetti; Roberta Bona; Pasqualina Leone; Mary E Klotman; Andrea Cara
Journal:  J Biomed Biotechnol       Date:  2010-05-19

3.  Vaccination with lentiviral vector expressing the nfa1 gene confers a protective immune response to mice infected with Naegleria fowleri.

Authors:  Jong-Hyun Kim; Hae-Jin Sohn; Jinyoung Lee; Hee-Jong Yang; Yong-Joon Chwae; Kyongmin Kim; Sun Park; Ho-Joon Shin
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

4.  Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques.

Authors:  Anne-Sophie Beignon; Karine Mollier; Christelle Liard; Frédéric Coutant; Sandie Munier; Julie Rivière; Philippe Souque; Pierre Charneau
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

5.  Controllable inhibition of hepatitis B virus replication by a DR1-targeting short hairpin RNA (shRNA) expressed from a DOX-inducible lentiviral vector.

Authors:  Weiwei Wang; Hongquan Peng; Jiafu Li; Xiping Zhao; Fei Zhao; Kanghong Hu
Journal:  Virus Genes       Date:  2013-02-09       Impact factor: 2.332

6.  Development and use of SIV-based Integrase defective lentiviral vector for immunization.

Authors:  Zuleika Michelini; Donatella R M Negri; Silvia Baroncelli; Massimo Spada; Pasqualina Leone; Roberta Bona; Mary E Klotman; Andrea Cara
Journal:  Vaccine       Date:  2009-06-11       Impact factor: 3.641

Review 7.  Vaccines: from empirical development to rational design.

Authors:  Christine Rueckert; Carlos A Guzmán
Journal:  PLoS Pathog       Date:  2012-11-08       Impact factor: 6.823

Review 8.  An Update on the HIV DNA Vaccine Strategy.

Authors:  Joseph Hokello; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  Vaccines (Basel)       Date:  2021-06-05

9.  Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines.

Authors:  Donatella R M Negri; Alessandra Rossi; Maria Blasi; Zuleika Michelini; Pasqualina Leone; Maria Vincenza Chiantore; Silvia Baroncelli; Gemma Perretta; Andrea Cimarelli; Mary E Klotman; Andrea Cara
Journal:  Retrovirology       Date:  2012-08-22       Impact factor: 4.602

10.  A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria.

Authors:  Frédéric Coutant; Raul Yusef Sanchez David; Tristan Félix; Aude Boulay; Laxmee Caleechurn; Philippe Souque; Catherine Thouvenot; Catherine Bourgouin; Anne-Sophie Beignon; Pierre Charneau
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.